Cited 0 times in Scipus Cited Count

Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series

DC Field Value Language
dc.contributor.authorVester, JC-
dc.contributor.authorBuzoianu, AD-
dc.contributor.authorFlorian, SI-
dc.contributor.authorHömberg, V-
dc.contributor.authorKim, SH-
dc.contributor.authorLee, TMC-
dc.contributor.authorMatula, C-
dc.contributor.authorPoon, WS-
dc.contributor.authorSandesc, D-
dc.contributor.authorvon Steinbüchel, N-
dc.contributor.authorStrilciuc, S-
dc.contributor.authorVos, PE-
dc.contributor.authorvon Wild, K-
dc.contributor.authorMuresanu, D-
dc.date.accessioned2023-01-05T03:03:30Z-
dc.date.available2023-01-05T03:03:30Z-
dc.date.issued2021-
dc.identifier.issn1590-1874-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23712-
dc.description.abstractIntroduction: This prospective meta-analysis summarizes results from the CAPTAIN trial series, evaluating the effects of Cerebrolysin for moderate-severe traumatic brain injury, as an add-on to usual care. Materials and methods: The study included two phase IIIb/IV prospective, randomized, double-blind, placebo-controlled clinical trials. Eligible patients with a Glasgow Coma Score (GCS) between 6 and 12 received study medication (50 mL of Cerebrolysin or physiological saline solution per day for ten days, followed by two additional treatment cycles with 10 mL per day for 10 days) in addition to usual care. The meta-analysis comprises the primary ensembles of efficacy criteria for 90, 30, and 10 days after TBI with a priori ordered hypotheses based on multivariate, directional tests. Results: A total 185 patients underwent meta-analysis (mean admission GCS = 10.3, mean age = 45.3, and mean Baseline Prognostic Risk Score = 2.8). The primary endpoint, a multidimensional ensemble of functional and neuropsychological outcome scales indicated a “small-to-medium” sized effect in favor of Cerebrolysin, statistically significant at Day 30 and at Day 90 (Day 30: MWcombined = 0.60, 95%CI 0.52 to 0.66, p = 0.0156; SMD = 0.31; OR = 1.69; Day 90: MWcombined = 0.60, 95%CI 0.52 to 0.68, p = 0.0146; SMD = 0.34, OR = 1.77). Treatment groups showed comparable safety and tolerability profiles. Discussion: The meta-analysis of the CAPTAIN trials confirms the safety and efficacy of Cerebrolysin after moderate-severe TBI, opening a new horizon for neurorecovery in this field. Integration of Cerebrolysin into existing guidelines should be considered after careful review of internationally applicable criteria.-
dc.language.isoen-
dc.subject.MESHAmino Acids-
dc.subject.MESHBrain Injuries, Traumatic-
dc.subject.MESHClinical Trials, Phase III as Topic-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeuroprotective Agents-
dc.subject.MESHProspective Studies-
dc.subject.MESHRandomized Controlled Trials as Topic-
dc.subject.MESHTreatment Outcome-
dc.titleCerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series-
dc.typeArticle-
dc.identifier.pmid33620612-
dc.subject.keywordCerebrolysin-
dc.subject.keywordModerate-severe traumatic brain injury-
dc.contributor.affiliatedAuthorKim, SH-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s10072-020-04974-6-
dc.citation.titleNeurological sciences-
dc.citation.volume42-
dc.citation.number11-
dc.citation.date2021-
dc.citation.startPage4531-
dc.citation.endPage4541-
dc.identifier.bibliographicCitationNeurological sciences, 42(11). : 4531-4541, 2021-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1590-3478-
dc.relation.journalidJ015901874-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurosurgery
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse